Skip to content

Study · Case report or series · n = 1 · 2026

5 results

Discontinuation of palopegteriparatide in chronic hypoparathyroidism without rebound hypocalcemia.

Rejnmark L, Underbjerg L

JCEM case reports13 Oct 2026

PMID42871663 (opens in a new tab)DOI10.1210/jcemcr/luag308 (opens in a new tab)PepBankPUB-42871663
Publisher pagePubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

  1. 01HumanCase report or seriesSafety outcome

    After palopegteriparatide discontinuation, a woman with hypoparathyroidism resumed calcium doses similar to those before hormone therapy.

    In plain wordsAfter palopegteriparatide discontinuation, a woman with hypoparathyroidism resumed calcium doses similar to those before hormone therapy.

    Peptide
    Palopegteriparatide
    Outcome
    Not applicableCalcium supplement requirements after discontinuation
    Study

    n = 1

    Outcome group
    Conventional therapy requirements · Endocrine and hormones
    Studied dose
    Dose not stated · more than 4 yearsAs given in this study (human).

    Source sentences

    Summary
    After discontinuation of palopegteriparatide, the patient resumed conventional treatment with calcium supplements and active vitamin D at doses similar to those used before starting hormone therapy
    1 context sentence
    Summary · context
    A woman with chronic hypoparathyroidism following total thyroidectomy was treated with palopegteriparatide, a long-acting parathyroid hormone replacement therapy, for more than 4 years.
  2. 02HumanCase report or seriesSafety outcome

    After palopegteriparatide discontinuation, a woman resumed active vitamin D doses similar to pretreatment doses, then reduced alfacalcidol because of high-normal calcium.

    In plain wordsAfter palopegteriparatide discontinuation, a woman resumed similar vitamin D doses, then reduced alfacalcidol because of high-normal calcium.

    Peptide
    Palopegteriparatide
    Outcome
    Not applicableActive vitamin D requirements after discontinuation
    Study

    n = 1

    Outcome group
    Conventional therapy requirements · Endocrine and hormones
    Studied dose
    Dose not stated · more than 4 yearsAs given in this study (human).

    Source sentences

    Summary
    After discontinuation of palopegteriparatide, the patient resumed conventional treatment with calcium supplements and active vitamin D at doses similar to those used before starting hormone therapy; the alfacalcidol dose was subsequently reduced because of high-normal calcium levels.
    1 context sentence
    Summary · context
    A woman with chronic hypoparathyroidism following total thyroidectomy was treated with palopegteriparatide, a long-acting parathyroid hormone replacement therapy, for more than 4 years.
  3. 03HumanCase report or seriesSafety outcome

    After palopegteriparatide discontinuation, a woman with hypoparathyroidism had no hypocalcemia symptoms on conventional therapy.

    In plain wordsAfter palopegteriparatide discontinuation, a woman with hypoparathyroidism had no hypocalcemia symptoms on conventional therapy.

    Peptide
    Palopegteriparatide
    Outcome
    Not applicableHypocalcemia symptoms after discontinuation
    Study

    n = 1

    Outcome group
    Adverse events · Endocrine and hormones
    Studied dose
    Dose not stated · more than 4 yearsAs given in this study (human).

    Source sentences

    Summary
    She remained clinically stable without symptoms of hypocalcemia or hungry bone syndrome, and repeated blood tests showed normal calcium levels throughout follow-up.
    1 context sentence
    Summary · context
    A woman with chronic hypoparathyroidism following total thyroidectomy was treated with palopegteriparatide, a long-acting parathyroid hormone replacement therapy, for more than 4 years.
  4. 04HumanCase report or seriesSafety outcome

    After palopegteriparatide discontinuation, a woman with hypoparathyroidism had no hungry bone syndrome on conventional therapy.

    In plain wordsAfter palopegteriparatide discontinuation, a woman with hypoparathyroidism had no hungry bone syndrome on conventional therapy.

    Peptide
    Palopegteriparatide
    Outcome
    Not applicableHungry bone syndrome after discontinuation
    Study

    n = 1

    Outcome group
    Adverse events · Endocrine and hormones
    Studied dose
    Dose not stated · more than 4 yearsAs given in this study (human).

    Source sentences

    Summary
    She remained clinically stable without symptoms of hypocalcemia or hungry bone syndrome, and repeated blood tests showed normal calcium levels throughout follow-up.
    1 context sentence
    Summary · context
    A woman with chronic hypoparathyroidism following total thyroidectomy was treated with palopegteriparatide, a long-acting parathyroid hormone replacement therapy, for more than 4 years.
  5. 05HumanCase report or seriesSafety outcome

    After palopegteriparatide discontinuation, repeated blood tests showed normal calcium throughout follow-up in a woman receiving conventional therapy.

    In plain wordsAfter palopegteriparatide discontinuation, a woman receiving conventional therapy maintained normal calcium throughout follow-up.

    Peptide
    Palopegteriparatide
    Outcome
    Not applicableSerum calcium after discontinuation
    Study

    n = 1

    Outcome group
    Adverse events · Endocrine and hormones
    Studied dose
    Dose not stated · more than 4 yearsAs given in this study (human).

    Source sentences

    Summary
    She remained clinically stable without symptoms of hypocalcemia or hungry bone syndrome, and repeated blood tests showed normal calcium levels throughout follow-up.
    1 context sentence
    Summary · context
    A woman with chronic hypoparathyroidism following total thyroidectomy was treated with palopegteriparatide, a long-acting parathyroid hormone replacement therapy, for more than 4 years.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:37 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.